Mesenchymal Stem Cell-Derived Exosomes

Phase 2Cell therapy

FFirst Affiliated Hospital of Guangxi Medical University

Mesenchymal Stem Cell-Derived Exosomes is one of 73 biologic programs targeting Endothelial Dysfunction. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endothelial DysfunctionActive, not recruiting

Oral MucositisActive, not recruiting

Endothelial DysfunctionPhase 1/Phase 2

Active, not recruiting

Oral MucositisPhase 2

Active, not recruiting

Competition

Competitive Landscape

132 competitors in Oral Mucositis

#DrugCompanyPhaseTrials

Afinitor

Novartis

Phase 3

1 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

2 4

Duragesic

CCephalon

Phase 3

2 5

Neurontin

VViatris Specialty LLC

Phase 3

1 6

Bactroban

PPadagis LLC

Phase 3

1 7

Benadryl

PParkedale

Phase 3

1 8

Curcumin

Merck & Co.

Phase 3

2 9

N-Acetyl Cyteien

SStanford University

Phase 3

2 10

Zinc Acetate

NNobelpharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Recruiting

Endothelial Dysfunction

NCT07183384

Q1 2028

Phase 2Not yet recruiting

Oral Mucositis

NCT07312656

Clinical

Trials by Indication[1]

Endothelial Dysfunction1 trial

MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction

Recruiting·UUniversitas Padjadjaran·Phase 1/2·NCT07183384·80 enrolled

Oral Mucositis1 trial

Aerosolized Mesenchymal Stem Cell-Derived Exosomes for the Prevention and Treatment of Radiation-Induced Oral Mucositis

Not yet recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT07312656·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Mesenchymal Stem Cell-Derived Exosomes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mesenchymal Stem Cell-Derived Exosomes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mesenchymal Stem Cell-Derived Exosomes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Guangxi Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: FFirst Affiliated Hospital of Guangxi Medical University

Mesenchymal Stem Cell-Derived Exosomes

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2028

Trials by Indication[1]

Endothelial Dysfunction1 trial

Oral Mucositis1 trial

References

Drug Info

Quick Facts

Related News